Tatsu...The agreement between Amarin and Mochida,for which Amarin paid Mochida $2 million of their precious funds in 2015,contains the following clause... QUOTE "The COLLABORATION is focused on the DEVELOPMENT and commercialization of early-stage drug products and indications based on the omega-3 acid, EPA (eicosapentaenoic acid)."...I would assume this covers your concerns.....This is NOT just a purchase of MND-2199, but a plan to DEVELOP it in partnership with Mochida and commercialize it everywhere, but in Japan as the agreement spells out.
Why would Amarin have made this investment if it could then be lost due to a change of ownership?...John Thero, the CEO of Amarin at the time, was not stupid.
News 
Market Data 
Discover 
AI
